Merck & Co. predicts it will make between $5 billion and $7 billion in sales of its potentially game-changing new oral COVID-19 drug in 2022, assuming it’s granted regulatory authorization this year.
Merck & Co. Inc. predicts it will make between $5 billion and $7 billion in sales of its potentially game-changing new oral COVID-19 drug in 2022, assuming it’s granted regulatory authorization this year.
If molnupiravir is authorized, it will be the first oral pill that people can take at home to keep them from getting sick enough to end up in the hospital or die. The clinical trial showed that the drug can reduce the risk of getting hospitalized or dying from a COVID-19 infection by 50%. “Coronavirus disease is going to be with us for the foreseeable future, even if it goes endemic,” Dr. Carl Dieffenbach, director of the AIDS division at NIAID and the official running the government’s $3.2 billion COVID-19 antiviral program, told MarketWatch this month. “These pills could be incredibly valuable [in] keeping the brushfire beaten down.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
U.S. drug company Merck to share license for experimental covid-19 treatment with non-profitU.S. pharmaceutical giant Merck has agreed to share its license with a non-profit so that its experimental covid-19 drug, molnupiravir, can be manufactured widely around the world in a deal that would expand access in more than 100 countries
Read more »
Merck signs pact to broaden generic manufacturing of COVID-19 pillMerck & Co has signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment, the U.S. drugmaker and the organization announced on Wednesday.
Read more »
COVID-19 vaccine harming child's fertility top concern for parents: PollA Kaiser Family Foundation poll found two-thirds of parents were concerned the vaccine could harm their child's fertility in the future.
Read more »
S.Africa's Aspen aims to sharply increase COVID-19 vaccine capacitySouth Africa's Aspen Pharmacare is aiming to ramp up its COVID-19 vaccine manufacturing capacity to 1.3 billion doses a year by February 2024, up from a current annual output of around 250 million doses, the company's CEO told Reuters on Monday.
Read more »
U.K., Canada Lead West in Weaning Economies Off Covid-19 Pandemic SupportThe U.K. dialed back government stimulus for the fast-growing British economy, one of the first big Western economies to step away from the emergency policies
Read more »
Inside In-N-Out Burger's escalating war with California over COVID-19 vaccine rulesLos Angeles’ impending crackdown could be an important test of the In-N-Out chain’s resistance to rules requiring proof of vaccination. The ordinance requires proof of vaccination to eat inside restaurants or to enter malls and other indoor venues.
Read more »